Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Aimmune Therap (NQ: AIMT )

34.49 USD UNCHANGED
Last Price Updated: 7:11 PM EDT, Oct 12, 2020 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Aimmune Therap

< Previous 1 2 3 4 5 6 7 Next >
Aimmune Therapeutics to Present Data on Peanut Allergy at ACAAI and PAAM Medical Meetings
Aimmune Therapeutics to present data on peanut allergy at ACAAI and PAAM medical meetings. 
From Business Wire News Releases
Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy
Aimmune Therapeutics announces clinical collaboration to study AR101 with Regeneron and Sanofi’s dupilumab for peanut allergy 
From Business Wire News Releases
Aimmune Therapeutics to Participate in Three Investor Conferences in September
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team... 
From Business Wire News Releases
Aimmune Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16th
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CFO Eric Bjerkholt will present a company overview... 
From Business Wire News Releases
Aimmune Therapeutics Announces Second Quarter 2017 Financial Results
Aimmune Therapeutics reports financial results for the second quarter ended June 30, 2017. 
From Business Wire News Releases
Aimmune Therapeutics’ Investigational Treatment for Peanut Allergy Featured in Science Translational Medicine Publication on Discovery of New TH2 Cell Subset Specific to Allergy
Aimmune's AR101 for peanut allergy in Science Translational Medicine article by Benaroya Research Institute on new TH2 subset specific to allergy. 
From Business Wire News Releases
Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
Aimmune Therapeutics enrolls first patient in ARTEMIS (ARC010) European Phase 3 clinical trial of AR101 for the treatment of peanut allergy. 
From Business Wire News Releases
Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress
Aimmune Therapeutics presents European Phase 3 PALISADE screening data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress. 
From Business Wire News Releases
Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017
Aimmune Therapeutics will present data on peanut allergy in Europe at the 2017 EAACI Congress in Helsinki on Tuesday, June 20. 
From Business Wire News Releases
Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy
Aimmune Therapeutics reports on up-dosing in its ongoing Phase 3 trial of AR101 in patients with peanut allergy. 
From Business Wire News Releases
Aimmune Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15th
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that CFO Eric Bjerkholt will present a company overview... 
From Business Wire News Releases
Aimmune Therapeutics Cuts Ribbon on Commercial Manufacturing Facility to Support Potential Launch of Treatment for Peanut Allergy
Aimmune Therapeutics celebrated the completion of its commercial manufacturing facility in Clearwater, Florida, which will support the potential launch of AR101 treatment for peanut allergy. 
From Business Wire News Releases
Aimmune Therapeutics Enrolls First Patient in RAMSES (ARC007), a Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
Aimmune Therapeutics enrolls first patient in RAMSES, a Phase 3 clinical trial of AR101 for the treatment of peanut allergy 
From Business Wire News Releases
Aimmune Therapeutics to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16
Aimmune Therapeutics will present at the Bank of America Merrill Lynch Healthcare Conference on May 16th at 1 p.m. Pacific Time. 
From Business Wire News Releases
Aimmune Therapeutics Announces First Quarter 2017 Financial Results
Aimmune Therapeutics announces first quarter financial results. 
From Business Wire News Releases
Aimmune Therapeutics Appoints Eric Bjerkholt as Chief Financial Officer
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), today announced the appointment of Eric Bjerkholt as Chief Financial Officer. 
From Business Wire News Releases
Aimmune Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today... 
From Business Wire News Releases
Aimmune Therapeutics to Release Fourth Quarter and Full Year 2016 Financial Results on Wednesday, March 15, 2017
Aimmune Therapeutics will announce 4Q and full year 2016 financial results on March 15, 2017, before U.S. markets open. 
From Business Wire News Releases
Aimmune Therapeutics Presents Clinical Data on Phase 3 Screening and Phase 2 Adherence for AR101 for Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Aimmune presented clinical data for AR101 for peanut allergy at AAAAI, including insights from Phase 3 screening (largest screening data set ever collected) and Phase 2 data supporting 95% adherence. 
From Business Wire News Releases
Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences in March
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today... 
From Business Wire News Releases
Aimmune Therapeutics to Present AR101 Clinical Data in Peanut Allergy at the 2017 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Aimmune will present AR101 clinical data in peanut allergy at the 2017 AAAAI annual meeting on March 6 in Atlanta, Georgia. 
From Business Wire News Releases
Aimmune Therapeutics Provides Update on Ongoing AR101 Phase 3 Program for Peanut Allergy Based on FDA Feedback
Aimmune provides update on AR101 Phase 3 program for peanut allergy based on FDA feedback; program to initially address ages 4-17, consistent with Breakthrough Therapy Designation patient population. 
From Business Wire News Releases
Aimmune Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
Aimmune Therapeutics to present at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, at 5 p.m. Pacific Time. 
From Business Wire News Releases
Aimmune Therapeutics Appoints Scientific Advisory Board of World-Renowned Food Allergy Experts
Aimmune announced its Scientific Advisory Board of leading food allergy researchers: Dr. Kirsten Beyer, Dr. A. Wesley Burks, Dr. Thomas Casale, Dr. Jonathan Hourihane, and Dr. Stacie Jones. 
From Business Wire News Releases
Aimmune Therapeutics Completes Global Enrollment of Phase 3 PALISADE Trial of AR101 for the Treatment of Peanut Allergy
Aimmune Therapeutics announced that it has completed global enrollment of its Phase 3 PALISADE trial of AR101 for the treatment of peanut allergy. 
From Business Wire News Releases
Aimmune Therapeutics Closes $145 Million Investment by Nestlé Health Science
Aimmune Therapeutics closes $145 million investment by Nestle Health Science 
From Business Wire News Releases
Aimmune Therapeutics to Host Investor Symposium Featuring Leading Experts in Peanut Allergy
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today... 
From Business Wire News Releases
Aimmune Therapeutics Announces Third Quarter 2016 Financial Results and Provides Corporate Update
Aimmune announces financial results for 3Q 2016 and provides a corporate update. 
From Business Wire News Releases
Aimmune Therapeutics Announces $145 Million Equity Investment by Nestlé Health Science, Demonstrating Shared Commitment to Advancing Food Allergy Therapeutics
Aimmune Therapeutics announces $145 million equity investment by Nestlé Health Science, demonstrating shared commitment to advancing food allergy therapeutics. 
From Business Wire News Releases
Aimmune Therapeutics to Participate in Two Upcoming Investor Conferences
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing CODIT™ (Characterized Oral Desensitization ImmunoTherapy) treatments for life-threatening food allergies, today... 
From Business Wire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
X